Activated protein C peptides for radio-mitigation

ABSTRACT
The purpose of the proposed grant application is to further develop a therapeutic
regimen focused on radiological nuclear medical countermeasuresVery few medical
products have been shown to counter the acute and long term injuries that can result
from a nuclear or radiological accident or attackMedical products and regimens that
mitigate and or treat radiation injury post exposurei eadministration of first dose to
start at leasthours after radiation exposurewith emphasis on broad activityi emulti syndrome and or multi tissueease of administration in a mass casualty and
emergency scenariosafetyand long shelf life are still to be developed and are thus of
high priorityTherapeutic administration of recombinant proteins to lethally irradiated
wild type mice resulted in mitigation of lethal total body irradiationThese findings
suggest that pharmacologic augmentation of the activity such proteins might offer a
rational approach to the mitigation of tissue injury and lethality caused by ionizing
radiation